Inovio Pharmaceuticals Inc vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.16 (market cap $28.69M). The key difference: Inovio Pharmaceuticals Inc is far larger — about 3.9× YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF's market cap, and YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF is more actively traded (22,490 versus 3,201,278). Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF for 60 Days on average.
| INO | QDTY | |
|---|---|---|
Market Cap | $112.19M | $28.69M |
Volume | 3,201,278 | 22,490 |
Sector | Health | Income / Options Overlay |
52-Week High | $2.65 | $46.71 |
52-Week Low | $0.66 | $36.57 |
Typical Hold Time | 43 Days | 60 Days |
Enterprise Value | $83.51M | — |
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →